Purpose: Gastrointestinal stromal tumor (GIST) has been considered radiation-resistant and data on the radiotherapy for GIST in previous studies are lacking. The purpose of this article is to accumulate more experience in the application of radiotherapy for GISTs. Materials and methods: Review our own case material and the relevant English literature. Results: A huge pelvic GIST after resistance to tyrosine kinase inhibitors (TKIs) has been well controlled by simultaneous-integrated boost intensity-modulated radiation therapy (SIB-IMRT). The time from the initial shrinkage of the mass and subsequent stabilization to now was more than 18 months. The patient was palliated from the series of symptoms caused by tumor compression and well tolerated to the adverse reactions by radiotherapy. And the previous studies have shown that GISTs had a certain sensitivity to radiotherapy. Conclusion: SIB-IMRT may provide a new means of achieving objective response and prolonging survival in selected GIST patients.
References
[1]
Aznab, M. and Akhmadi, S.M. (2018) Long-Term Results of Adjuvant Imatinib Treatment for Localized Gastrointestinal Stromal Tumors after Surgery. Asian Pacific Journal of Cancer Prevention, 19, 39-43.
[2]
Demetri, G.D., von Mehren, M., Antonescu, C.R., DeMatteo, R.P., Ganjoo, K.N., Maki, R.G., et al. (2010) NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors. JournaloftheNationalComprehensiveCancerNetwork, 8, S-1-S-41. https://doi.org/10.6004/jnccn.2010.0116
[3]
Ihle, M.A., Huss, S., Jeske, W., Hartmann, W., Merkelbach-Bruse, S., Schildhaus, H., et al. (2018) Expression of Cell Cycle Regulators and Frequency of TP53 Mutations in High Risk Gastrointestinal Stromal Tumors Prior to Adjuvant Imatinib Treatment. PLOSONE, 13, e0193048. https://doi.org/10.1371/journal.pone.0193048
[4]
Efared, B., Atsame-Ebang, G., Tahiri, L., Sidibé, I.S., Erregad, F., Hammas, N., et al. (2018) The Expression of MDM2 in Gastrointestinal Stromal Tumors: Immunohistochemical Analysis of 35 Cases. BMCClinicalPathology, 18, Article No. 2. https://doi.org/10.1186/s12907-018-0069-0
[5]
Moodley, J., Cutz, J. and Schell, M. (2018) Reactive Nodular Fibrous Pseudotumor Mimicking Metastatic Gastrointestinal Stromal Tumor to Perigastric Lymph Node: A Case Report and Review of the Literature. InternationalJournalofSurgicalPathology, 26, 664-670. https://doi.org/10.1177/1066896918771192
[6]
Li, J., Ye, Y., Wang, J., Zhang, B., Qin, S., Shi, Y., et al. (2017) Chinese Consensus Guidelines for Diagnosis and Management of Gastrointestinal Stromal Tumor. ChineseJournalofCancerResearch, 29, 281-293. https://doi.org/10.21147/j.issn.1000-9604.2017.04.01
[7]
Shen, C., Chen, H., Yin, Y., Chen, J., Zhang, B., Chen, Z., et al. (2014) Preoperative Imatinib for Patients with Primary Unresectable or Metastatic/Recurrent Gastrointestinal Stromal Tumor. Clinics, 69, 758-762. https://doi.org/10.6061/clinics/2014(11)09
[8]
Lim, K.T. (2017) Surgical Treatment of Gastrointestinal Stromal Tumors of the Stomach: Current Status and Future Perspective. TranslationalGastroenterologyandHepatology, 2, 104-104. https://doi.org/10.21037/tgh.2017.12.01
[9]
Montemurro, M., Cioffi, A., Dômont, J., Rutkowski, P., Roth, A.D., von Moos, R., et al. (2018) Long-Term Outcome of Dasatinib First-Line Treatment in Gastrointestinal Stromal Tumor: A Multicenter, 2-Stage Phase 2 Trial (Swiss Group for Clinical Cancer Research 56/07). Cancer, 124, 1449-1454. https://doi.org/10.1002/cncr.31234
[10]
Kasireddy, V. and von Mehren, M. (2017) Emerging Drugs for the Treatment of Gastrointestinal Stromal Tumour. ExpertOpiniononEmergingDrugs, 22, 317-329. https://doi.org/10.1080/14728214.2017.1411479
[11]
Rutkowski, P., Jagielska, B., Andrzejuk, J., Bylina, E., Lugowska, I., Switaj, T., et al. (2017) The Analysis of the Long-Term Outcomes of Sorafenib Therapy in Routine Practice in Imatinib and Sunitinib Resistant Gastrointestinal Stromal Tumors (Gist). WspółczesnaOnkologia, 21, 285-289. https://doi.org/10.5114/wo.2017.72393
[12]
Röper, B., Heinrich, C., Kehl, V., Rechl, H., Specht, K., Wörtler, K., et al. (2015) Study of Preoperative Radiotherapy for Sarcomas of the Extremities with Intensity-Modulation, Image-Guidance and Small Safety-Margins (PREMISS). BMCCancer, 15, Article No. 904. https://doi.org/10.1186/s12885-015-1633-y
[13]
Wang, D., Zhang, Q., Eisenberg, B.L., Kane, J.M., Li, X.A., Lucas, D., et al. (2015) Significant Reduction of Late Toxicities in Patients with Extremity Sarcoma Treated with Image-Guided Radiation Therapy to a Reduced Target Volume: Results of Radiation Therapy Oncology Group RTOG-0630 Trial. JournalofClinicalOncology, 33, 2231-2238. https://doi.org/10.1200/jco.2014.58.5828
[14]
Lolli, C., Pantaleo, M.A., Nannini, M., Saponara, M., Pallotti, M.C., Di Scioscio, V., et al. (2011) Successful Radiotherapy for Local Control of Progressively Increasing Metastasis of Gastrointestinal Stromal Tumor. RareTumors, 3, 153-154. https://doi.org/10.4081/rt.2011.e49
[15]
de Moura, L.R., Marshall, J., Di Cesare, S., Fernandes, B.F., Antecka, E. and Burnier, M.N. (2012) The Effect of Imatinib Mesylate on the Proliferation, Invasive Ability, and Radiosensitivity of Retinoblastoma Cell Lines. Eye, 27, 92-99. https://doi.org/10.1038/eye.2012.231
[16]
Ozkan, E.E. (2018) Radiotherapy for Gastrointestinal Stromal Tumors. ChineseMedicalJournal, 131, 235-240. https://doi.org/10.4103/0366-6999.222344
[17]
Cuaron, J.J., Goodman, K.A., Lee, N. and Wu, A.J. (2013) External Beam Radiation Therapy for Locally Advanced and Metastatic Gastrointestinal Stromal Tumors. RadiationOncology, 8, Article No. 274. https://doi.org/10.1186/1748-717x-8-274
[18]
Huang, W.L., Long, Q., Lu, W.L., Jiang, Q.F., Tan, B.X., Tian, L.J., Luo, Y., Xiao, Y. and Fang, W.J. (2016) Clinical Effects of IMRT and Simultaneous Integrated Boost-Intensity Modulated Radiation Therapy: A Comparative Study of 277 Patients with Advanced Cervical Cancer. International Journal of Radiation Medicine and Nu-clear Medicine, 40, 429-434.
[19]
Aparicio, T., Boige, V., Sabourin, J.-., Crenn, P., Ducreux, M., Le Cesne, A., et al. (2004) Prognostic Factors after Surgery of Primary Resectable Gastrointestinal Stromal Tumours. EuropeanJournalofSurgicalOncology (EJSO), 30, 1098-1103. https://doi.org/10.1016/j.ejso.2004.06.016
[20]
Crosby, J.A., Catton, C.N., Davis, A., Couture, J., O’Sullivan, B., Kandel, R., et al. (2001) Malignant Gastrointestinal Stromal Tumors of the Small Intestine: A Review of 50 Cases from a Prospective Database. AnnalsofSurgicalOncology, 8, 50-59. https://doi.org/10.1007/s10434-001-0050-4
[21]
Boruban, C., Sencan, O., Akmansu, M., Atik, E.T. and Ozbek, S. (2007) Metastatic Gastrointestinal Stromal Tumor with Long-Term Response after Treatment with Concomitant Radiotherapy and Imatinib Mesylate. Anti-CancerDrugs, 18, 969-972. https://doi.org/10.1097/cad.0b013e3280e94982
[22]
Gatto, L., Nannini, M., Saponara, M., Di Scioscio, V., Beltramo, G., Frezza, G.P., et al. (2017) Radiotherapy in the Management of Gist: State of the Art and New Potential Scenarios. ClinicalSarcomaResearch, 7, Article No. 1. https://doi.org/10.1186/s13569-016-0065-z
[23]
Pollock, J., Morgan, D., Denobile, J. and Williams, J. (2001) CASE REPORT: Adjuvant Radiotherapy for Gastrointestinal Stromal Tumor of the Rectum. DigestiveDiseasesandSciences, 46, 268-272. https://doi.org/10.1023/a:1005581000712
